CRISPR/Cas9敲除miR-21增强K562/G01细胞伊马替尼敏感性
该研究用CRISPR/Cas9敲除耐伊马替尼的K562/G01细胞系中miR-21,获得3个单细胞克隆,突变效率7.12%~8.11%。敲除后细胞增殖受抑、克隆形成率下降、伊马替尼IC50降低,机制涉及抑制PI3K/AKT通路及下调BCR-ABL表达。
要点
- miR-21敲除抑制K562/G01细胞增殖并降低克隆形成率。
- 敲除miR-21后伊马替尼IC50显著下降,药物敏感性提高。
- 机制可能与抑制PI3K/AKT通路及下调BCR-ABL表达相关。
核心结论
- 敲除miR-21可抑制K562/G01细胞增殖并提高其对伊马替尼的敏感性。
- 该效应可能通过抑制PI3K/AKT信号通路和下调BCR-ABL表达实现。
研究设计与样本
- 体外细胞研究,使用耐伊马替尼的人慢性髓性白血病细胞株K562/G01。
- 采用CRISPR/Cas9敲除miR-21,经PCR筛选、Sanger测序和实时定量PCR获得单细胞克隆。
- 用MTT法、克隆形成实验评估增殖,用MTT法和Annexin Ⅴ-APC/7-AAD双染流式检测伊马替尼敏感性。
- 用Western blot检测PTEN、AKT、p-AKT、PI3K、p-PI3K、P210(BCR-ABL)、p-P210(BCR-ABL)蛋白表达。
主要发现
- 成功构建3个miR-21敲除的K562/G01单细胞克隆,CRISPR/Cas9介导的突变效率为7.12%~8.11%。
- 野生型和1#、2#、6#单细胞克隆的克隆形成率依次为(57.67±8.25)%、(26.94±5.36)%、(7.17±2.11)%、(31.50±3.65)%,差异有统计学意义(P<0.05)。
- 野生型和1#、2#、6#单细胞克隆对伊马替尼的IC50值分别为(21.92±1.36)µmol/ml、(3.98±0.39)µmol/ml、(5.38±1.01)µmol/ml、(9.24±1.36)µmol/ml,差异有统计学意义(P<0.05)。
- miR-21敲除后PTEN蛋白表达未见明显变化,但PI3K、AKT信号分子活化受抑,P210(BCR-ABL)和p-P210(BCR-ABL)蛋白表达下调。
关键数值与推荐
- miR-21敲除使K562/G01细胞克隆形成率由野生型(57.67±8.25)%降至(7.17±2.11)%~(31.50±3.65)%。
- miR-21敲除使伊马替尼IC50由野生型(21.92±1.36)µmol/ml降至(3.98±0.39)~(9.24±1.36)µmol/ml。
临床怎么用
- 提示miR-21可能作为慢性髓性白血病伊马替尼耐药的潜在干预靶点。
- 为后续联合抑制miR-21与酪氨酸激酶抑制剂克服耐药提供体外实验依据。
局限性
- 研究仅基于K562/G01细胞系体外实验,未涉及原代细胞或动物模型。
- miR-21调控伊马替尼敏感性的完整分子网络尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the effects of miR-21 knockout on proliferation and drug resistance in K562/G01 cells, and to preliminarily explore the mechanism of imatinib sensitivity by knocking out miR-21 in K562/G01 cells. Methods: Using CRISPR/Cas9 to knock out the miR-21 gene in K562/G01 cells, and single-cell-derived clones of miR-21 knockout were obtained by genomic DNA PCR screening, Sanger sequencing, and real-time PCR. We used MTT and cell colony formation assays to assess the cell proliferation, and determined imatinib sensitivity by MTT assay and Annexin-Ⅴ-APC/7-AAD double staining flow cytometry. Using western blot, we examined the potential mechanisms affecting imatinib sensitivity by knocking out miR-21 in K562/G01 cells. Results: Three miR-21 knockout K562/G01 single-cell-derived clones were successfully constructed. The mutation efficiency mediated by CRISPR/Cas9 was 7.12%-8.11%. MiR-21 knockout inhibited the proliferation of K562/G01 cells; the clone formation rates of WT and 1#, 2#, 6# K562/G01 single-cell clones were (57.67±8.25) %, (26.94± 5.36) %, (7.17±2.11) %, (31.50±3.65) %, respectively. MiR-21 knockout increased the sensitivity of K562/G01 cells to imatinib, IC(50) of imatinib in WT, and 1#, 2#, 6# K562/G01 single-cell clones were (21.92±1.36) µmol/ml, (3.98±0.39) µmol/ml, (5.38±1.01) µmol/ml, (9.24±1.36) µmol/ml. After the knockout of miR-21, the activation of PI3K/Akt signaling molecules was inhibited, while the expression of P210(B)CR-ABL and p-P210(BCR-ABL) was downregulated; however, the expression of PTEN was not affected. Conclusion: The knockout of miR-21 can suppress cell proliferation and improve sensitivity to imatinib in K562/G01 cells, which may be achieved by inhibiting the PI3K/AKT signaling pathway and BCR-ABL expression. 目的: 观察microRNA-21(miR-21)敲除对耐伊马替尼的人慢性髓性白血病细胞株K562/G01细胞在增殖、药物敏感性等方面的影响,初步探讨miR-21影响K562/G01细胞伊马替尼敏感性的可能机制。 方法: 运用CRISPR/Cas9技术敲除K562/G01细胞的miR-21,经PCR筛选、Sanger测序鉴定和实时定量PCR检测获得miR-21敲除的单细胞克隆。扩增培养后,采用MTT法、细胞克隆形成实验检测miR-21敲除对K562/G01细胞增殖的影响。使用伊马替尼处理细胞后,用MTT法和Annexin Ⅴ-APC/7-AAD双染流式细胞检测法观察敲除miR-21后K562/G01细胞对伊马替尼的敏感性的变化。Western blot法检测miR-21敲除前后K562/G01细胞PTEN、AKT、p-AKT、PI3K、p-PI3K、P210(BCR-ABL)、p-P210(BCR-ABL)蛋白表达量的变化。 结果: 成功构建了3个miR-21敲除的K562/G01单细胞克隆,CRISPR/Cas9介导的突变效率为7.12%~8.11%。miR-21敲除使K562/G01细胞的增殖受抑,野生型和1#、2#、6#单细胞克隆的克隆形成率依次为(57.67±8.25)%、(26.94±5.36)%、(7.17±2.11)%、(31.50±3.65)%,差异有统计学意义(P<0.05)。miR-21敲除使K562/G01细胞对伊马替尼的敏感性增加,野生型和1#、2#、6#单细胞克隆对伊马替尼的IC(50)值分别为(21.92±1.36)µmol/ml、(3.98±0.39)µmol/ml、(5.38±1.01)µmol/ml、(9.24±1.36)µmol/ml,差异有统计学意义(P<0.05)。miR-21敲除后,其靶基因PTEN的蛋白表达水平未见明显变化,但PI3K、AKT信号分子的活化受到抑制,并且P210(BCR-ABL)、p-P210(BCR-ABL)蛋白表达也下调。 结论: miR-21敲除抑制K562/G01细胞增殖,提高其对伊马替尼的敏感性,这可能是通过抑制PI3K/AKT信号通路和BCR-ABL表达实现的。.
引用
- Zhang Y, Wang LY, Li JZ, et al. [CRISPR/Cas9-mediated microRNA-21 knockout increased imatinib sensitivity in chronic myeloid leukemia cells]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33910311. doi:10.3760/cma.j.issn.0253-2727.2021.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。